1. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/ AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ ASPC/ NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13-e115. doi:10.1161/HYP.0000000000000065 2. Mancia G, Rea F, Corrao G, Grassi G. Two-Drug Combinations as First-Step Antihypertensive Treatment. Circ Res. 2019;124(7):1113-1123. doi:10.1161/circresaha.118.313294 3. Schmieder RE, Wassmann S, Predel HG, et al. Improved Persistence to Medication, Decreased Cardiovascular Events and Reduced All-Cause Mortality in Hypertensive Patients with Use of Single-Pill Combinations: Results from the STARTStudy. 2023. Hypertension. 2023;80(5):1127-1135. doi:10.1161/hypertensionaha.122.20810 4. Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P. Prevalence of Apparent TreatmentResistant Hypertension in the United States: Comparison of the 2008 and 2018 American Heart Association Scientific Statements on Resistant Hypertension. Hypertension. 2019;73(2):424-431. doi:10.1161/hypertensionaha.118.12191 5. Carey RM, Calhoun DA, Bakris GL, et al. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018;72(5):e53-e90. doi:10.1161/ hyp.0000000000000084 6. Hamrahian SM, Maarouf OH, Fülöp T. A Critical Review of Medication Adherence in Hypertension: Barriers and Facilitators Clinicians Should Consider. Patient Preference and Adherence. 2022; 16: 27492757. doi:10.2147/PPA.S368784 7. Burnier M, Egan BM. Adherence in Hypertension: A Review of Prevalence, Risk Factors, Impact, and Management. Circ Res. 2019;124(7):1124-1140. doi:10.1161/circresaha.118.313220 8. Domino FJ. Improving Adherence to Treatment for Hypertension. Am Fam Physician. 2005;71(11):208990. https://www.aafp.org/pubs/afp/ issues/2005/0601/p2089.html 9. Kulkarni S, Graggaber J. How to Improve Compliance to Hypertension Treatment. e-Journal of Cardiology Practice. 2022; 22(6). https://www. escardio.org/Journals/E-Journal-of-CardiologyPractice/Volume-22/how-to-improve-complianceto-hypertension-treatment 10. Dziedziak J, Zaleska-Żmijewska A, Szaflik JP, Cudnoch-Jędrzejewska A. Impact of Arterial Hypertension on the Eye: A Review of the Pathogenesis, Diagnostic Methods, and Treatment of Hypertensive Retinopathy. Med Sci Monit. 2022;28:e935135. doi:10.12659/msm.935135 11. Williams B, MacDonald TM, Morant S, et al. Spironolactone Versus Placebo, Bisoprolol, and Doxazosin to Determine the Optimal Treatment for Drug-Resistant Hypertension (PATHWAY-2): A Randomised, Double-Blind, Crossover Trial. Lancet. 2015;386(10008):2059-2068. doi:10.1016/S01406736(15)00257-3 12. Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334-1357. doi:10.1161/ hypertensionaha.120.15026 13. Hypertension Center Certification. AHA. www.heart.org/en/professional/qualityimprovement/healthcare-certification/ hypertension-center-certification 14. Barbato, E, et al. Renal Denervation In the Management of Hypertension In Adults. European Heart Journal. 2023;44(15):1313-1330. doi:10.1093/ eurheartj/ehad054 15. Kandzari DE, Böhm M, Mahfoud F, et al. Effect of Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 6-Month Efficacy and Safety Results From the SPYRAL HTN-ON MED Proof-Of-Concept Randomised Trial. Lancet. 2018;391(10137):2346-2355. doi:10.1016/s01406736(18)30951-6 16. Böhm M, Kario K, Kandzari DE, et al. Efficacy of Catheter-Based Renal Denervation in the Absence of Antihypertensive Medications (SPYRAL HTN-off MED Pivotal): A Multicentre, Randomized, ShamControlled Trial. Lancet. 2020;395(10234):1444-1451. doi:10.1016/s0140-6736(20)30554-7 17. Ogunniyi MO, Commodore-Mensah Y, Ferdinand KC. Race, Ethnicity, Hypertension, and Heart Disease. JACC. 2021;78(24):2460-2470. doi:10.1016/j. jacc.2021.06.017 18. Ferdinand KC, Yadav K, Nasser SA, et al. Disparities in Hypertension and Cardiovascular Disease in Blacks: The Critical Role of Medication Adherence. Journal of Clinical Hypertension. 2017;19(10):10151024. doi:10.1111/jch.13089 19. Abrahamowicz AA, Ebinger J, Whelton SP, Commodore-Mensah Y, Yang E. Racial and Ethnic Disparities in Hypertension: Barriers and Opportunities to Improve Blood Pressure Control. Current Cardiology Reports. 2023;25(1):17-27. doi:10.1007/s11886-022-01826-x 20. Manohar SA, Charbonnet RM, Reddy TK, Ferdinand KC. Improving Hypertension Control in Vulnerable Populations Around the World. Current Cardiology Reports. 2023;25(10):1319-1326. doi:10.1007/s11886023-01947-x 21. Milani, RV, Price-Haywood EG, Burton JH, Wilt J, Entwisle J, Lavie CJ. Racial Differences and Social Determinants of Health in Achieving Hypertension Control. 2022. Mayo Clin Proc. 2022;97(8):1462-1471. doi:10.1016/j.mayocp.2022.01.035 22. Joo HJ, Yum, Y, Kim, YH, et al. Gender Difference of Blood Pressure Control Rate and Clinical Prognosis in Patients with Resistant Hypertension: RealWorld Observational Study. J Korean Med Sci. 2023;38(16):e124. doi:10.3346/jkms.2023.38.e124 23. Noubiap JJ, Nansseu JR, Nyaga UF, Sime PS, Francis I, Bigna JJ. Global Prevalence of Resistant Hypertension: A Meta-Analysis of Data from 3.2 Million Patients. Heart. 2018;105(2):98-105. doi:10.1136/heartjnl-2018-313599 24. Shallcross AJ, Butler M, Tanner RM, et al. Psychosocial Correlates of Apparent TreatmentResistant Hypertension in the Jackson Heart Study. Journal of Human Hypertension. 2017;31(7):474-478. doi:10.1038/jhh.2016.100 25. Himmelfarb CRD, Beckie TM, Allen LA, et al. Shared Decision-Making and Cardiovascular Health: A Scientific Statement From the American Heart Association. Circulation. 2023;148(11):912-931. doi:10.1161/cir.0000000000001162 26. Choudhry NK, Kronish IM, Vongpatanasin W, et al. Medication Adherence and Blood Pressure Control. A Scientific Statement from the American Heart Association. Hypertension. 2022;79(1):e1-e14. doi:10.1161/HYP.0000000000000203 27. Kask-Flight L, Durak K, Suija K, Rätsep A, Kalda R. Reduction of Cardiovascular Risk Factors Among Young Men With Hypertension Using an Interactive Decision Aid: Cluster-Randomized Control Trial. BMC Cardiovascular Disorders. 2021;21(1):543. doi:10.1186/ s12872-021-02339-1 28. Olomu A, Khan NNS, Todem D, et al. Blood Pressure Control in Hypertensive Patients in Federally Qualified Health Centers: Impact of Shared Decision Making in the Office-GAP Program. MDM Policy & Practice. 2016;1(1):2381468316656010. doi:10.1177/2381468316656010 29. Hanlin RB, Asif IM, Wozniak G, et al. Measure Accurately, Act Rapidly, and Partner With Patients (MAP) Improves Hypertension Control in Medically Underserved Patients: Care Coordination Institute and American Medical Association Hypertension Control Project Pilot Study Results. Journal of Clinical Hypertension. 2018;20(1):79-87. doi:10.1111/jch.13141 30. Langford AT, Williams SK, Applegate M, Ogedegbe O, Braithwaite RS. Partnerships to Improve Shared Decision Making for Patients with Hypertension: Health Equity Implications. Ethnicity & Disease. 2019;29(Suppl 1):97-102. doi:10.18865/ed.29.s1.97 31. Naik AD, Kallen MA, Walder A, Street RL. Improving Hypertension Control in Diabetes Mellitus: The Effects of Collaborative and Proactive Health Communication. Circulation. 2008;117(11):1361-1368. doi:10.1161/circulationaha.107.724005 32. The SHARE Approach: A Model for Shared Decision Making. Agency for Healthcare Research and Quality. www.ahrq.gov/shareddecisionmaking 33. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023;389(24):2221-2232. doi:10.1056/ nejmoa2307563 34. Cluett JL, Blazek O, Brown AL, et al. Renal Denervation for the Treatment of Hypertension: A Scientific Statement From the American Heart Association. Hypertension. 2024;81:e1524-4563. doi:10.1161/hyp.0000000000000240 References 23
RkJQdWJsaXNoZXIy MjI2NjI=